Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Cardiol Rev. 2011 May;7(2):67-71. doi: 10.2174/157340311797484204.

Immunologic considerations in heart transplantation for congenital heart disease.

Author information

  • 1Children's Hospital of Philadelphia, Philadelphia, PA 19104-4399, USA. kaufmanb@email.chop.edu

Abstract

Children and adults with congenital heart disease (CHD) can require interventions that result in immunologic alterations that are different than those seen in patients with cardiomyopathies. Patients with CHD can be exposed to heart surgeries, blood products, valved and non-valved allograft tissue, and mechanical circulatory support, all of which can alter the immunologic status of these patients. This change in immunologic status is most commonly manifested as the development of anti-human leukocyte antigen (HLA) antibodies. This review will delineate a) the causes of anti-HLA anti-body production (often referred to as allosensitization); b) preventive strategies for anti-HLA antibody production before transplantation; c) treatment strategies for those patients who develop anti-HLA antibodies before transplantation; d) consequences of HLA allosensitization after transplantation; and e) treatment of HLA allosensitization and antibody-mediated rejection after transplantation.

KEYWORDS:

Heart transplantation; allosensitization; management.; pediatric; rejection; therapy

PMID:
22548029
[PubMed - indexed for MEDLINE]
PMCID:
PMC3197091
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
    Loading ...
    Write to the Help Desk